A Bibliometric Analysis of Global Research Trends in Psoriasis and Metabolic Syndrome

References

• Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21–28. doi:10.1016/j.clindermatol.2017.09.005
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Bavoso NC, Pinto JM, Soares MMS, Diniz MDS, Teixeira Júnior AL. Psoriasis in obesity: comparison of serum levels of leptin and adiponectin in obese subjects - cases and controls. An Bras Dermatol. 2019;94(2):192–197. doi:10.1590/abd1806-4841.20197716
   PubMed Web of Science ®Google Scholar
• Liu Y, Li X, Huang YP, et al. Association of polymorphisms of metabolism-related genes with psoriasis vulgaris in Han Chinese. Biomed Res Int. 2021;2021:9920631. doi:10.1155/2021/9920631
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: vOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3
   PubMed Web of Science ®Google Scholar
• Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One. 2019;14(10):e0223994. doi:10.1371/journal.pone.0223994
   PubMed Web of Science ®Google Scholar
• Ma D, Yang B, Guan B, et al. A bibliometric analysis of pyroptosis from 2001 to 2021. Front Immunol. 2021;12:731933. doi:10.3389/fimmu.2021.731933
   PubMed Web of Science ®Google Scholar
• Liu T, Yang L, Mao H, Ma F, Wang Y, Zhan Y. Knowledge domain and emerging trends in podocyte injury research from 1994 to 2021: a bibliometric and visualized analysis. Front Pharmacol. 2021;12:772386. doi:10.3389/fphar.2021.772386
   PubMed Web of Science ®Google Scholar
• Zhu X, Hu J, Deng S, et al. Bibliometric and visual analysis of research on the links between the gut microbiota and depression from 1999 to 2019. Front Psychiatry. 2021;11:587670. doi:10.3389/fpsyt.2020.587670
   PubMed Web of Science ®Google Scholar
• Qin A, Sun J, Gao C, Li C. Bibliometrics analysis on the research status and trends of adult-onset Still’s disease: 1921–2021. Front Immunol. 2022;13:950641. doi:10.3389/fimmu.2022.950641
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen P, Miao L. A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022. Front Immunol. 2022;13:969196. doi:10.3389/fimmu.2022.969196
   PubMed Web of Science ®Google Scholar
• Yang S, Zhao S, Ye Y, Jia L, Lou Y. Global research trends on the links between gut microbiota and cancer immunotherapy: a bibliometric analysis (2012–2021). Front Immunol. 2022;13:952546. doi:10.3389/fimmu.2022.952546
   PubMed Web of Science ®Google Scholar
• Chen C, Dubin R, Kim MC. Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014). Expert Opin Biol Ther. 2014;14(9):1295–1317. doi:10.1517/14712598.2014.920813
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–835. doi:10.1016/j.jaad.2006.08.040
   PubMed Web of Science ®Google Scholar
• Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi:10.1007/s00403-006-0703-z
   PubMed Web of Science ®Google Scholar
• Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68–73. doi:10.1111/j.1365-2133.2007.07986.x
   PubMed Web of Science ®Google Scholar
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562. doi:10.1038/jid.2011.365
   PubMed Web of Science ®Google Scholar
• Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–46. doi:10.1016/j.jdermsci.2011.03.002
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–151. doi:10.2340/00015555-0770
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88(5):1242–1247. doi:10.3945/ajcn.2008.26427
   PubMed Web of Science ®Google Scholar
• Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the national health and nutrition examination survey, 2003–2006. Arch Dermatol. 2011;147(4):419–424. doi:10.1001/archdermatol.2010.370
   PubMedGoogle Scholar
• Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273–1277. doi:10.1136/annrheumdis-2012-201299
   PubMed Web of Science ®Google Scholar
• Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379–382. doi:10.1001/archdermatol.2009.48
   PubMedGoogle Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi:10.1001/jama.296.14.1735
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. doi:10.1016/j.jaad.2012.08.015
   PubMed Web of Science ®Google Scholar
• Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–67. doi:10.1111/j.0022-202X.2005.23681.x
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi:10.1111/j.1600-0625.2011.01261.x
   PubMed Web of Science ®Google Scholar
• Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785–1796. doi:10.1038/jid.2010.103
   PubMed Web of Science ®Google Scholar
• Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614–621. doi:10.1016/j.jaad.2005.11.1079
   PubMed Web of Science ®Google Scholar
• Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527–1534. doi:10.1001/archderm.141.12.1527
   PubMed Web of Science ®Google Scholar
• Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007;56(4):629–634. doi:10.1016/j.jaad.2006.09.017
   PubMed Web of Science ®Google Scholar
• Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses’ Health Study II. Arch Intern Med. 2007;167(15):1670–1675. doi:10.1001/archinte.167.15.1670
   PubMed Web of Science ®Google Scholar
• Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895–902. doi:10.1111/j.1365-2133.2008.08707.x
   PubMed Web of Science ®Google Scholar
• Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700–703. doi:10.1001/archdermatol.2009.94
   PubMedGoogle Scholar
• Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152–155. doi:10.1159/000111512
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144(12):1571–1575. doi:10.1001/archderm.144.12.1571
   PubMedGoogle Scholar
• Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–1006. doi:10.1093/eurheartj/ehp567
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. doi:10.1038/nutd.2012.26
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–1024. doi:10.1016/j.jaad.2013.06.053
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and management of psoriasis and associated comorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.339
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol. 2012;166(1):204–207. doi:10.1111/j.1365-2133.2011.10539.x
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Krueger JG. Lipoprotein metabolism and inflammation in patients with psoriasis. Am J Cardiol. 2016;118(4):603–609. doi:10.1016/j.amjcard.2016.05.060
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Gormsen LC, Vendelbo MH, Egeberg A, Nielsen J, Iversen L. Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017;176(3):732–740. doi:10.1111/bjd.15149
   PubMed Web of Science ®Google Scholar
• Gupta Y, Möller S, Zillikens D, Boehncke WH, Ibrahim SM, Ludwig RJ. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. Exp Dermatol. 2013;22(8):552–553. doi:10.1111/exd.12192
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen H, Nikamo P, et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol. 2013;133(3):836–839. doi:10.1038/jid.2012.366
   PubMed Web of Science ®Google Scholar
• Gerdes S, Osadtschy S, Buhles N, Baurecht H, Mrowietz U. Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol. 2014;23(5):322–325. doi:10.1111/exd.12381
   PubMed Web of Science ®Google Scholar
• Koch M, Baurecht H, Ried JS, et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol. 2015;135(5):1283–1293. doi:10.1038/jid.2015.8
   PubMed Web of Science ®Google Scholar
• Milčić D, Janković S, Vesić S, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol. 2017;92(1):46–51. doi:10.1590/abd1806-4841.20175178
   PubMedGoogle Scholar
• Kim HN, Han K, Park YG, Lee JH. Metabolic syndrome is associated with an increased risk of psoriasis: a nationwide population-based study. Metabolism. 2019;99:19–24. doi:10.1016/j.metabol.2019.07.001
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Zarchi K, et al. The association of metabolic syndrome and psoriasis: a population- and hospital-based cross-sectional study. J Eur Acad Dermatol Venereol. 2015;29(3):490–497. doi:10.1111/jdv.12595
   PubMed Web of Science ®Google Scholar
• Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019;180(1):94–99. doi:10.1111/bjd.16885
   PubMed Web of Science ®Google Scholar
• Meziane M, Kelati A, Najdi A, Berraho A, Nejjari C, Mernissi FZ. Metabolic syndrome in Moroccan patients with psoriasis. Int J Dermatol. 2016;55(4):396–400. doi:10.1111/ijd.12623
   PubMed Web of Science ®Google Scholar
• Mebazaa A, El Asmi M, Zidi W, et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. J Eur Acad Dermatol Venereol. 2011;25(6):705–709. doi:10.1111/j.1468-3083.2010.03856.x
   PubMed Web of Science ®Google Scholar
• Danielsen K, Wilsgaard T, Olsen AO, et al. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. Br J Dermatol. 2015;172(2):419–427. doi:10.1111/bjd.13288
   PubMed Web of Science ®Google Scholar
• Albareda M, Ravella A, Castelló M, Saborit S, Peramiquel L, Vila L. Metabolic syndrome and its components in patients with psoriasis. Springerplus. 2014;3:612. doi:10.1186/2193-1801-3-612
   PubMed Web of Science ®Google Scholar
• Lee HJ, Han KD, Park HE, et al. Changes in metabolic syndrome and risk of psoriasis: a nationwide population-based study. Sci Rep. 2021;11(1):24043. doi:10.1038/s41598-021-03174-2
   PubMed Web of Science ®Google Scholar
• Takahashi H, Iinuma S, Honma M, Iizuka H. Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease. J Dermatol. 2014;41(11):981–985. doi:10.1111/1346-8138.12632
   PubMed Web of Science ®Google Scholar
• Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital Dermatol Venereol. 2016;151(6):663–677.
   PubMed Web of Science ®Google Scholar
• Huang YH, Yang LC, Hui RY, et al. Relationships between obesity and the clinical severity of psoriasis in Taiwan. J Eur Acad Dermatol Venereol. 2010;24(9):1035–1039. doi:10.1111/j.1468-3083.2010.03573.x
   PubMed Web of Science ®Google Scholar
• Ma AR, Liu F, Wang R, et al. Prevalence of metabolic syndrome in Chinese patients with erythrodermic psoriasis: a case-control study. Front Endocrinol. 2021;12:677912. doi:10.3389/fendo.2021.677912
   PubMed Web of Science ®Google Scholar
• Chularojanamontri L, Wongpraparut C, Silpa-Archa N, Chaweekulrat P. Metabolic syndrome and psoriasis severity in South-East Asian patients: an investigation of potential association using current and chronological assessments. J Dermatol. 2016;43(12):1424–1428. doi:10.1111/1346-8138.13540
   PubMed Web of Science ®Google Scholar
• Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32(3):343–350. doi:10.1016/j.clindermatol.2013.11.001
   PubMed Web of Science ®Google Scholar
• Navarro SL, Kantor ED, Song X, et al. Factors associated with multiple biomarkers of systemic inflammation. Cancer Epidemiol Biomarkers Prev. 2016;25(3):521–531. doi:10.1158/1055-9965.EPI-15-0956
   PubMed Web of Science ®Google Scholar
• Pay JB, Shaw AM. Towards salivary C-reactive protein as a viable biomarker of systemic inflammation. Clin Biochem. 2019;68:1–8. doi:10.1016/j.clinbiochem.2019.04.006
   PubMed Web of Science ®Google Scholar
• Michels KB, Keller K, Pereira A, et al. Association between indicators of systemic inflammation biomarkers during puberty with breast density and onset of menarche. Breast Cancer Res. 2020;22(1):104. doi:10.1186/s13058-020-01338-y
   PubMed Web of Science ®Google Scholar
• Uysal S, Yılmaz FM, Karatoprak K, Artüz F, Cumbul NU. The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. Eur Rev Med Pharmacol Sci. 2014;18(22):3453–3458.
   PubMed Web of Science ®Google Scholar
• Lin YC, Dalal D, Churton S, et al. Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res. 2014;66(1):97–103. doi:10.1002/acr.22144
   PubMed Web of Science ®Google Scholar
• Cai J, Cui L, Wang Y, Li Y, Zhang X, Shi Y. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis. Front Pharmacol. 2021;12:774808. doi:10.3389/fphar.2021.774808
   PubMed Web of Science ®Google Scholar
• Chandrashekar L, Kumarit GR, Rajappa M, Revathy G, Munisamy M, Thappa DM. 25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. Br J Biomed Sci. 2015;72(2):56–60. doi:10.1080/09674845.2015.11666797
   PubMed Web of Science ®Google Scholar
• Piaserico S, Orlando G, Messina F. Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways. Int J Mol Sci. 2022;23(16):9063. doi:10.3390/ijms23169063
   PubMed Web of Science ®Google Scholar
• Nosalski R, Guzik TJ. Perivascular adipose tissue inflammation in vascular disease. Br J Pharmacol. 2017;174(20):3496–3513. doi:10.1111/bph.13705
   PubMed Web of Science ®Google Scholar
• Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbaşi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008;159(4):820–826. doi:10.1111/j.1365-2133.2008.08742.x
   PubMed Web of Science ®Google Scholar
• Huang LH, Zinselmeyer BH, Chang CH, et al. Interleukin-17 drives interstitial entrapment of tissue lipoproteins in experimental psoriasis. Cell Metab. 2019;29(2):475–487.e7. doi:10.1016/j.cmet.2018.10.006
   PubMed Web of Science ®Google Scholar
• von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062. doi:10.1016/j.jid.2018.10.042
   PubMed Web of Science ®Google Scholar
• Belinchón I, Vanaclocha F, de la Cueva-Dobao P, et al. Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. J DermatolTreat. 2015;26(4):318–325. doi:10.3109/09546634.2014.983039
   Google Scholar
• Caso F, Del Puente A, Oliviero F, et al. Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol. 2018;37(3):579–586. doi:10.1007/s10067-017-3975-0
   PubMed Web of Science ®Google Scholar
• Edson-Heredia E, Zhu B, Lefevre C, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using clinical practice research datalink. J Eur Acad Dermatol Venereol. 2015;29(5):955–963. doi:10.1111/jdv.12742
   PubMed Web of Science ®Google Scholar
• Adeodato Ramos LM, Gomes KWP, de Saboia Mont’Alverne AR, Braga MV, Costa Vasconcelos AH, Rodrigues CEM. High prevalence of metabolic syndrome in patients with psoriatic arthritis from northeastern Brazil: association with traditional cardiovascular risk factors and biologic disease-modifying antirheumatic drugs. J Clin Rheumatol. 2021;27(6S):S186–S192. doi:10.1097/RHU.0000000000001631
   PubMedGoogle Scholar
• Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res. 2011;63(2):195–202. doi:10.1002/acr.20363
   PubMed Web of Science ®Google Scholar
• Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41(7):1357–1365. doi:10.3899/jrheum.140021
   PubMed Web of Science ®Google Scholar
• Özkan SG, Yazısız H, Behlül A, Gökbelen YA, Borlu F, Yazısız V. Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis. Eur J Rheumatol. 2017;4(1):40–45. doi:10.5152/eurjrheum.2017.16052
   PubMed Web of Science ®Google Scholar
• Carneiro S, Palominos PE, Anti SMA, et al. Brazilian society of rheumatology 2020 guidelines for psoriatic arthritis. Adv Rheumatol. 2021;61(1):69. doi:10.1186/s42358-021-00219-y
   PubMedGoogle Scholar
• Song Z, Deng X, Xie W, Li B, Zhang Z. Clinical characteristics of psoriatic arthritis in Chinese patients: a cross-sectional study. Rheumatol Ther. 2021;8(4):1845–1857. doi:10.1007/s40744-021-00384-y
   PubMed Web of Science ®Google Scholar
• Caso F, Postiglione L, Covelli B, et al. Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset ”sine psoriasis”. Clin Rheumatol. 2019;38(9):2547–2552. doi:10.1007/s10067-019-04619-w
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;12(12):1299–1308. doi:10.1080/1744666X.2016.1201423
   PubMed Web of Science ®Google Scholar
• Caso F, Chimenti MS, Navarini L, et al. Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Rev Clin Immunol. 2020;16(4):409–420. doi:10.1080/1744666X.2020.1740593
   PubMed Web of Science ®Google Scholar
• Eder L, Jayakar J, Pollock R, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2013;72(12):1956–1961. doi:10.1136/annrheumdis-2012-202325
   PubMed Web of Science ®Google Scholar
• Feld J, Nissan S, Eder L, et al. Increased prevalence of metabolic syndrome and adipocytokine levels in a psoriatic arthritis cohort. J Clin Rheumatol. 2018;24(6):302–307. doi:10.1097/RHU.0000000000000721
   PubMed Web of Science ®Google Scholar
• Vachatova S, Andrys C, Krejsek J, et al. Metabolic syndrome and selective inflammatory markers in psoriatic patients. J Immunol Res. 2016;2016:5380792. doi:10.1155/2016/5380792
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology. 2017;233(5):378–389. doi:10.1159/000481882
   PubMed Web of Science ®Google Scholar
• Wolk K, Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17(3):305–317. doi:10.1007/s11154-016-9381-0
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):273–281. doi:10.1111/bjd.16437
   PubMed Web of Science ®Google Scholar
• Dikbas O, Tosun M, Bes C, Tonuk SB, Aksehirli OY, Soy M. Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis. 2016;19(7):672–677. doi:10.1111/1756-185X.12444
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022;45(7):1277–1288. doi:10.1007/s40618-022-01755-0
   PubMed Web of Science ®Google Scholar
• Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656–662. doi:10.1111/jdv.12847
   PubMed Web of Science ®Google Scholar
• Ortolan A, Lorenzin M, Tadiotto G, et al. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin Rheumatol. 2019;38(10):2843–2850. doi:10.1007/s10067-019-04646-7
   PubMed Web of Science ®Google Scholar
• Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol. 2014;171(1):17–29. doi:10.1111/bjd.12941
   PubMed Web of Science ®Google Scholar
• Perez-Carreras M, Casis-Herce B, Rivera R, Fernandez I, Martinez-Montiel P, Villena V. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: inflammatory cross-talk that needs a multidisciplinary approach. World J Gastroenterol. 2021;27(41):7113–7124. doi:10.3748/wjg.v27.i41.7113
   PubMed Web of Science ®Google Scholar
• Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci. 2016;17(2):217. doi:10.3390/ijms17020217
   PubMed Web of Science ®Google Scholar
• Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179(1):16–29. doi:10.1111/bjd.16239
   PubMed Web of Science ®Google Scholar
• de Morales JMG R, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. doi:10.1016/j.autrev.2019.102429
   PubMed Web of Science ®Google Scholar
• Gomes AL, Teijeiro A, Burén S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161–175. doi:10.1016/j.ccell.2016.05.020
   PubMed Web of Science ®Google Scholar
• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113. doi:10.1016/j.jaad.2018.11.058
   PubMed Web of Science ®Google Scholar
• Dauden E, Blasco AJ, Bonanad C, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2018;32(12):2058–2073. doi:10.1111/jdv.15177
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–1433. doi:10.1080/14712598.2022.2113872
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):537–552. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar